Autres langues Valneva

Actions

VLA

FR0004056851

Recherche biotechnologique et médicale

PEA

PEA/PME

Marché Fermé - Euronext Paris Autres places de cotation 17:55:00 09/02/2026			Varia. 5j.	Varia. 1 janv.
4,120 ^EUR	+2,28 %		+5,97 %	+10,81 %

05/02	Avis d'analystes du jour : les objectifs s'ajustent sur Renault, Soitec, Crédit Agricole et Alten
05/02	Ça tangue sévère pour l'argent, le bitcoin et une partie de la tech

Autres langues

03/02	Global markets live: SpaceX, Tesla, Boeing, PayPal, AstraZeneca…
03/02	Valneva, Instituto Butantan Start Pilot Program for Chikungunya Vaccine in Brazil
03/02	Valneva to Run Chikungunya Vaccine Pilot Program in Brazil
03/02	Valneva and Instituto Butantan start pilot chikungunya vaccination campaign in Brazil
03/02	Valneva initiates pilot vaccination strategy in Brazil
03/02	Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
03/02	Valneva Se and Instituto Butantan Announce Initiation of Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine Ixchiq
20/01	Valneva Provides Update on Chikungunya Vaccine IXCHIQ
20/01	French and Benelux stocks-Factors to watch
20/01	Valneva to Pull Regulatory Filings for Chikungunya Vaccine After US FDA Clinical Hold
19/01	Valneva SE Provides Update on Chikungunya Vaccine IXCHIQ
19/01	Valneva withdraws application for standard US approval of its chikungunya shot
19/01	Valneva Provides Update on Chikungunya Vaccine IXCHIQ®
12/01	Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
09/01	Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
01/01	Valneva, Serum Institute of India End Chikungunya Vaccine License Deal
31/12	Sector Update: Health Care Stocks Softer Late Afternoon
31/12	Sector Update: Health Care
31/12	Valneva SE Terminates Vaccine Deal with Serum Institute
31/12	Valneva SE and Serum Institute of India Announces Discontinuation of Chikungunya Vaccine License Agreement
31/12	Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
10/12	Valneva reports positive phase 2 results in children for Chikungunya vaccine
10/12	Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
10/12	Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
27/11	Valneva Plans to Consolidate Operations in France, Research, Development Activities in Austria

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse Idées de trading

Filtres

A la une

Valneva : le grand retour de l'euphorie sur les biotechs ?

Le 12 août 2025 à 18:01